Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone/Bupropion after Sleeve Gastrectomy
NCT06620562Phase 4Recruiting
- Sponsor
- Université Laval
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Naltrexone/Bupropion with Placebo (2 arms). Primary endpoints: Weight loss at 24 months and Percentage of participant with an Excess Weight Loss above 50% at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06620562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620562.